Congenital heart defects with pulmonary hypertension
Authors:
T. Zatočil; A. Nečasová; T. Brychta
Authors place of work:
Ambulance vrozených srdečních vad v dospělosti, Interní kardiologická klinika, FN Brno-Bohunice
Published in the journal:
Kardiol Rev Int Med 2009, 11(4): 174-177
Category:
Sympozium
Summary
Congenital heart defects with pulmonary hypertension represent small but heterogeneous group with the most pronounced symptoms and the worst long‑term prognosis. Owing to the advances in cardiology and cardiac surgery and, of course, pre‑natal diagnostics, the number of these patients is not expected to increase. Presence of the left to right shunt is prerequisite to pulmonary hypertension. Pulmonary hypertension frequently results from shunts found behind the tricuspid valve, owing to the high pressure gradient between systemic and pulmonary circulation in these locations. Compensation of the pressures in the systemic and pulmonary circulation leads to reversal of the shunt and to cyanosis – Eisenmenger’s syndrome develops. Complications are frequent, with hypoxia as the common denominator; advanced stages are considered to be a multi‑systemic disease. Treatment is symptomatic, impact of any drug on balanced haemodynamics must be taken into account, modern treatments of pulmonary hypertension are advantageous, combined transplantation of the heart and lungs might be considered in terminally ill patients. Considering the complexity of these issues, these patients should be managed by the specialised centres.
Keywords:
congenital heart defects – pulmonary hypertension – Eisenberger’s syndrome – left-to-right shunt
Zdroje
1. Diller GP, Dimopoulos K, Okonko D et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation 2005; 112: 828–835.
2. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation 2007; 115(8): 1039–1050.
3. Beghetti M, Barst RJ, Naeije R et al. Pulmonary Arterial Hypertension Related to Congenital Heart Disease. Munich: Elsevier GmbH 2006: 1–228
4. Simonneau G, Galié N, Rubin LJ et al. Clinical classification of pulmorary hypertension. J Am Coll Cardiol 2004; 43: 5S–12S.
5. Celermajer DS, Cullen S, Deanfield JE. Impairment of endotelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation 1993; 87: 440–446.
6. Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol 1996; 28: 768–772.
7. ESC Guidelines on management of Grown-Up Congenital Heart Disease. European Heart J 2003; 24: 1035–1084.
8. Galié N, Beghetti M, Gatzoulis MA et al. Bosentan Randomized Trial of Endothelial Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double blind, randomized, placebo-controlled study. Circulation 2006; 114: 48–54.
Štítky
Paediatric cardiology Internal medicine Cardiac surgery CardiologyČlánok vyšiel v časopise
Cardiology Review
2009 Číslo 4
Najčítanejšie v tomto čísle
- Pleural effusion – aetiology and diagnostics
- Pulmonary embolism
- Congenital heart defects with pulmonary hypertension
- Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease